Elon Musk is back on top of Bloomberg's ranking of the richest people on earth. The billionaire lost his position to Bernard Arnault, who helms French high-fashion conglomerate LVMH, in December of 2022, as Tesla's stock declined significantly amid a broader market downturn.
But as the stock has recovered in early 2023, Musk's fortune has risen with it.
Shares of Tesla are up around 95 percent since January 1, and Musk's net worth was $187.1 billion at the close of markets on Monday, placing Arnault in second place with his $185.3 billion.
Now the big question is whether Tesla will keep up the momentum. The stock is still down more than 80 percent over the past 12 months, and the headwinds it faced in 2022 remain.
In particular, Musk remains saddled with making Twitter financially viable. On Saturday night, the social media platform laid off at least 200 people, which is roughly 10 percent the remaining 2,000 who work for the company. There were around 7,500 employees when Musk started making cuts to reduce costs.
In addition, waning demand for electric vehicles has forced Tesla to cut prices to move inventory. While the cuts have boosted sales, they remain sluggish in key markets such as China.
Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and what’s next for modern vet medicine.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
